Monitoring of in vitro protein synthesis
By using separate peptide systems and fluorescent protein tags in microfluidic devices, real-time monitoring of cell-free protein synthesis reactions is achieved, the problems of background interference and label influence are solved, and the stability and solubility of detection are improved.
Patent Information
- Application Number
- CN202380023192.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-23
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-01
AI Technical Summary
In microfluidic devices, it is difficult to detect proteins in cell-free protein synthesis reactions in real-time, especially due to background interference caused by high concentrations of other proteins and biomolecules, as well as increased size of fluorescent protein tags to the biological function and physics of proteins Due to the influence of characteristics, existing luminescence complementary methods cannot achieve long-term real-time detection.
In situ fluorescence monitoring is achieved by using separate peptide systems to transcription and translation of proteins fused to fluorescent protein tags in vitro and using polypeptides to monitor peptide tags to generate detectable signals, such as complementary ccGFP11 and ccGFP1-10 polypeptides.
Real-time monitoring of proteins in cell-free protein synthesis reactions is achieved, background interference is avoided, and the stability and solubility of fluorescence signals are improved, and it is suitable for long-term protein expression tracking.
Smart Images

Figure BDA0005005683170000031 
Figure BDA0005005683170000032 
Figure BDA0005005683170000041
Abstract
Description
Field of the Invention
[0001] Provided herein are methods and compositions for detecting protein synthesis with a device. The methods are suitable for monitoring on a microfluidic device. Background of the Invention
[0003] When cell-free protein synthesis is performed on a microfluidic scale in a microfluidic device, such as a digital microfluidic device, it is useful to detect proteins synthesized by the cell-free protein synthesis reaction in real time. However, it is difficult to perform real-time detection of proteins in a cell-free protein synthesis reaction environment. The reaction contains many other proteins and biomolecules in high concentrations, making it difficult to detect proteins by standard protein staining methods (e.g., Coomassie Brilliant Blue G-250, SYPRO TM Nonspecific protein detection using immunoprecipitation (e.g., Ruby, silver staining) is difficult. Immunostaining or affinity-based purification followed by nonspecific protein staining is also unhelpful because extensive washing must be performed on the solid support to prevent background interference. Background interference can become troublesome because washing is known to be difficult in microfluidic and digital microfluidic devices.
[0004] Currently available luminescence complementation methods cannot achieve long-term real-time detection in cell-free protein synthesis reactions, which often exceed 16 hours. This limitation is due to multiple reasons, including O2 consumption by luminescent enzymes competing with the O2 demand of cell-free protein synthesis and temporary or permanent exhaustion of luminescent substrates within the 3-24 hours of recombinant protein expression detection.
[0005] The protein of interest can also be expressed as a fusion with a fluorescent protein, such as green fluorescent protein (GFP). However, GFP is a 26.9 kDa protein, which is the typical size of most fluorescent proteins. Tags of this size increase the overall size of the protein of interest, especially if the protein of interest must be labeled with other large fusion proteins, such as maltose binding protein (MBP) of 42.5 kDa. Given that the average size of human proteins is about 52 kDa, and the average size of E. coli proteins is about 35 kDa (Kim, YE et al., Annu. Rev. Biochem. 2013. 82: 323-355), adding a fluorescent protein tag of comparable size will significantly change the biological function and biophysical properties of the protein.
[0006] Many prior arts disclose the use of subcomponent tags for monitoring expression in cell systems. For example, US Pat. No. 7,666,606 discloses a detection system for protein-protein interactions using microdomains.
[0007] Schinn et al., Biotechnol. Bioeng 11410, October 2017, 2412-2417 ( https: / / onlinelibrary.wiley.com / doi / 10.1002 / bit.2630 5) Publication of rapid in vitro screening of position-dependent effects of unnatural amino acids on protein expression and activity-Schinn-2017-Biotechnology and Bioengineering-Wiley Online Library.
[0008] Split green fluorescent protein (GFP) has been used for a variety of applications. ccGFP is a split green fluorescent protein engineered from a tetrameric GFP found in the ruby mushroom coral (Corynactis californica), a bright red, colonizing coral polyp similar to sea anemones and scleractinianstonycorals, as described in Nguyen et al.; Nature Scientific Reports volume 11, Article number: 18440 (2021). The inventors herein have optimized the use of ccGFP for cell-free protein synthesis.
[0009] Overview
[0010] Here, we report the surprising discovery that a split peptide system can be engineered to perform in situ, fluorescence-based monitoring of the expression of a protein of interest in a cell-free protein synthesis reaction. Monitoring can be performed on the device during the expression process and can therefore be used in real time or as an endpoint measurement.
[0011] Disclosed herein is a method for real-time monitoring of in vitro protein synthesis, comprising:
[0012] a. in vitro transcription and translation of a protein of interest fused to a peptide tag; and
[0013] b. Monitoring the presence of a peptide tag using other polypeptides that produce a detectable signal in the presence of the peptide tag.
[0014] Disclosed herein is a method for monitoring cell-free protein synthesis in droplets on a digital microfluidics device, comprising:
[0015] a. Cell-free transcription and translation of a protein of interest fused to a peptide tag; and
[0016] b. Monitoring the presence of a peptide tag using other polypeptides that produce a detectable signal in the presence of the peptide tag.
[0017] Disclosed herein is a method for monitoring cell-free protein synthesis in droplets on a digital microfluidics device, comprising:
[0018] a. Cell-free transcription and translation with ccGFP11 a peptide tag fused to a protein of interest; and
[0019] b. Use of additional ccGFP 1-10 Peptide monitoring for the presence of a peptide tag, the addition of ccGFP 1-10 Peptide in the ccGFP 11 The presence of the peptide tag generates a detectable signal.
[0020] The terms "in vitro" and "cell-free" are used interchangeably herein.
[0021] The detectable signal may be, for example, fluorescence or luminescence.The detectable signal may also result from the binding of the ligand to a complementary oligo-, peptide- or polypeptide tag fused to the protein of interest.
[0022] A detectable signal may also result from binding of the polypeptide to a protein of interest fused to a His-tag.
[0023] Any in vitro transcription and translation, such as extract-based systems derived from rabbit reticulocyte lysate, human lysate, Chinese hamster ovary lysate, wheat germ, HEK293 lysate, E. coli lysate, yeast lysate, can be used.
[0024] Alternatively, in vitro transcription and translation can be assembled from purified components, such as the Purified Recombinant Elements system (PURE).
[0025] In vitro transcription and translation can be coupled or uncoupled.
[0026] The peptide tag can be a component of a fluorescent protein, and the other polypeptide is a complementary part of the fluorescent protein. Fluorescent proteins can include sfGFP, GFP, eGFP, deGFP, frGFP, eYFP, eBFP, eCFP, Citrine, Venus, Cerulean, Dronpa, DsRED, mKate, mCherry, mRFP, FAST, SmURFP, miRFP670nano. For example, the peptide tag can be GFP 11 , other polypeptides can be GFP 1-10 The peptide tag may be a component of sfCherry. The peptide tag may be a component of sfCherry 11 , other polypeptides can be sfCherry 1-10 In the presence of a hydroxybenzylidene rhodanine analog, the peptide tag can be CFAST 11 or CFAST 10 , the other polypeptide may be NFAST.
[0027] The peptide tag can be ccGFP 11and another polypeptide may be ccGFP 1-10 .
[0028] For example, GFP 1-10 The amino acid sequence of the polypeptide may be derived from sfGFP:
[0029] SEQ ID NO: 1
[0030]
[0031] Alternatively, GFP 1-10 The polypeptide amino acid sequence can be further mutated from the above sequence to become brighter faster when complementary. The sequence can have greater than 90% homology with any sequence mentioned herein. The sequence can have greater than 95% homology with any sequence mentioned herein.
[0032] SEQ ID NO: 2
[0033]
[0034] GFP 1-10 The polypeptide amino acid sequence may also be derived from ccGFP and have greater than 90% or 95% homology to the following sequence:
[0035] SEQ ID NO: 3 (ccGFP 1-11 )
[0036]
[0037] SEQ ID NO: 4 (ccGFP 1-10 )
[0038]
[0039] SEQ ID NO 5 (ccGFP 1-10 )
[0040]
[0041] Expression seq ID No 5ccGFP 1-10 Nucleic acid sequence; SEQ ID NO: 6
[0042]
[0043] SEQ ID NO7
[0044]
[0045]
[0046] Expression seq ID No 7ccGFP 1-10 Nucleic acid sequence; SEQ ID NO: 8
[0047]
[0048] Complementation of GFP 11 The amino acid sequence of the peptide may be as follows:
[0049] 1.KRDHMVLLEFVTAAGITGT (SEQ ID NO: 9)
[0050] 2.KRDHMVLHEFVTAAGITGT (SEQ ID NO: 10)
[0051] 3.KRDHMVLHESVNAAGIT (SEQ ID NO: 11)
[0052] 4.RDHMVLHEYVNAAGIT (SEQ ID NO: 12)
[0053] 5.GDAVQIQEHAVAKYFTV (SEQ ID NO: 13)
[0054] 6.GDTVQLQEHAVAKYFTV (SEQ ID NO: 14)
[0055] 7.GETIQLQEHAVAKYFTE (SEQ ID NO: 15)
[0056] Or a truncated form thereof. The truncation may include shortening by up to 5 amino acids from the N-terminus, the C-terminus, or a combination thereof.
[0057] GFP 11 GFP 1-10 It can be fused to the protein of interest via an amino acid linker. In one embodiment, the oligopeptide, peptide or polypeptide linker can be 0-50 amino acids.
[0058] Also disclosed is a nucleic acid sequence for expressing a specific tag. The nucleic acid sequence includes
[0059] SEQ ID NO: 16
[0060]
[0061] SEQ ID NO: 17
[0062]
[0063] or a truncated form thereof.
[0064] These sequences can be repeated one or more times to generate multiple GFP 11 Domain-containing proteins.
[0065] For example, sfCherry 1-10 The amino acid sequence of a polypeptide can be:
[0066] SEQ ID NO: 18
[0067]
[0068] The complementary sfCherry11 peptide amino acid sequence can be:
[0069] SEQ ID NO: 19
[0070] YTIVEQYERAEGRHSTGG
[0071] sfCherry11 or sfCherry 1-10 It can be fused to the protein of interest via an amino acid linker. In one embodiment, the oligopeptide, peptide or polypeptide linker can be 0-50 amino acids.
[0072] For example, the amino acid sequence of a NFAST polypeptide may be:
[0073] SEQ IS NO:20
[0074]
[0075] The complementary CFAST11 peptide amino acid sequence can be:
[0076] SEQ ID NO: 21
[0077] GDSYWVFVKRV
[0078] Alternatively, the complementary CFAST10 peptide amino acid sequence can be:
[0079] SEQ ID NO: 22
[0080] GDSYWVFVKR
[0081] NFAST, CFAST11 and / or CFAST10 can be fused to the protein of interest via an amino acid linker. In one embodiment, the oligopeptide, peptide or polypeptide linker can be 0-50 amino acids.
[0082] The peptide tag may also be a component of a protein that forms a detectable substrate, such as a luminescent or chromogenic substrate. The protein may include β-galactosidase, β-lactamase or luciferase.
[0083] Proteins can be fused to multiple tags. For example, a protein can be fused to multiple GFP 11 Peptide tag fusion and multiple GFP 1-10 The synthesis occurs in the presence of a polypeptide. The GFP can be ccGFP or sfGFP. For example, a protein can be combined with multiple ccGFP 11 Peptide tag fusion and multiple ccGFP 1-10 The protein of interest can be synthesized in the presence of one or more sfCherry 11 Peptide tag and one or more GFP 11 Peptide tag fusion and one or more GFP 1-10 Peptide and one or more sfCherry 1-10 Synthesis occurs in the presence of polypeptides.
[0084] Any protein of interest can be synthesized. The protein can be an enzyme, such as terminal deoxynucleotidyl transferase (TdT) or a truncated form thereof, or a homologous amino acid sequence of terminal deoxynucleotidyl transferase (TdT) in other species, or a homologous amino acid sequence of Polμ, Polβ, Polλ and Polθ of any species, or a homologous amino acid sequence of X family polymerase of any species.
[0085] The synthesis can be performed in a microfluidic device, such as an electrowetting on dielectric (EWoD) device. Alternatively, the synthesis can be performed in a microtiter plate format. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] Figure 1 One embodiment of the present invention is schematically shown. The cell-free protein synthesis reaction comprises a nucleic acid template containing an expression cassette of a gene of interest fused to a detectable tag, which is then expressed into a protein of interest by coupled or uncoupled in vitro transcription and in vitro translation. Therefore, the protein of interest is fused to a detectable peptide tag at the N-terminus or C-terminus. The property of the detectable peptide tag is that it can complement a complementary polypeptide to produce a fluorescent protein.
[0088] Figure 2 The expression of the protein of interest in the cell-free protein synthesis reaction was detected in real time under blue light illumination. 11 _TdT was cloned into the p70a vector and added (2 μl, 30 nM) to MyTXTL Sigma70CFPS MasterMix (10 μl; Arbor Biosciences) to give a total reaction volume of 12 μl. 1-10The solution (0.9 mg / ml; 364 mM urea) was added to the CFPS reaction at 0, 1, 2, 3, 4, 6 and 12 μl, respectively, to obtain a final CFPS urea concentration of 0, 28, 51, 72, 90, 120 and 180 mM. The reaction was then incubated at 29°C in a 200 μl PCR tube. Photos were taken under a 470 nm blue light illuminator using a 580 nm filter.
[0089] Figure 3 Display the Figure 2 Real-time detection of the expression of a protein of interest in a cell-free protein synthesis reaction. Fluorescence measurements were performed at the indicated time points using an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 1-10 Solution without sfGFP 11 Negative control CFPS reaction of _TdTp70a plasmid was used to subtract background fluorescence.
[0090] Figure 4 (A) Droplets on a digital microfluidics device containing cell-free protein synthesis lysate are shown. The droplets marked with white arrows have been incubated with recombinant sfGFP. 1-10 The top two rows additionally contain DNA constructs for expressing sfGFP 11 (B) shows the same droplet as in panel (A) after six hours. 11 Expression of peptide-tagged proteins and recombinant sfGFP 1-10 Droplets with both polypeptides detected (i.e., solid arrows) showed a significant increase in fluorescence. Droplets without DNA constructs (open arrows) or without sfGFP 1-10 Droplets with the target (no arrow) are non-fluorescent. (C) Fluorescence quantification of droplets in panel (B). Only the droplets with lysate, DNA construct, and sfGFP 1-10 The droplets tested for the polypeptide showed a significant increase in fluorescence, indicating protein expression. The negative control, the bottom row of droplets in (B), contained no DNA construct and therefore had low fluorescence, even in the presence of sfGFP. 1-10 The same is true for the case of the detection object. The numbering of the droplets in (B) matches the bars in (C).
[0091] Figure 5 : Images extracted from a time course experiment where droplets of cell-free protein synthesis (CFPS) lysate, optionally with a protein of interest (POI - here sfGFP) were co-cultured with 11 Peptide-tagged maltose binding protein (MBP) and / or sfGFP 1-10The DNA constructs of the peptides were incubated on the digital microfluidics device for 4 hours and imaged periodically. 1-10 The polypeptide droplets showed a dramatic increase in fluorescence during the experiment, as seen in the right-hand column of images.
[0092] Figure 6 Show in Figure 5 Figure 2 shows the real-time fluorescence increase seen in the droplets presented in Figure 2. Quantification of fluorescence was performed in ImageJ by subtracting the fluorescence intensity of the CFPS lysate and sfGFP. 1-10 The values presented have been normalized to the background fluorescence seen in the droplets containing all components - lysate, DNA construct of POI and sfGFP. 1-10 The peptide-containing droplets produce fluorescence that exceeds the background.
[0093] Figure 7 In this experiment, recombinant purified sfGFP was used 1-10 Detection and encoding sfGFP 11 DNA constructs of the tagged proteins were added simultaneously to the cell-free lysate. The fluorescence signal was monitored over time using a plate reader. A graph showing the increase in fluorescence signal over time based on plate reader measurements of the CFPS reaction. sfGFP 1-10 The detector was present in all three reactions from the outset, allowing real-time monitoring of protein expression. 11 Tag fusion of the protein of interest under conditions with no sfGFP 11 Fluorescence increased compared to negative control conditions of the tagged proteins. POI1 is an engineered terminal transferase and POI2 is SARS-COV-NL63-Mpro. Both have 3xsfGFP at the N-terminus 11 Label.
[0094] Figure 5-7 Real-time detection of protein expression. 1-10 The detection peptide is present from the beginning of the experiment. The fluorescent signal increases with the sfGFP 11 The label is expressed and increased. These experiments were performed in a base fluid containing 0.2% Span 85 in dodecamethylpentasiloxane instead of an aqueous solution of Tween 20 and no surfactant in dodecane.
[0095] Figure 8 sfGFP 11 Tagging with recombinant GFP 1-10Complementation of the assays was inhibited in the presence of 0.1% weight / volume Tween20 surfactant. Complementation assays were performed in TNG buffer (50 mM Tris, pH 7.4, 0.1 M NaCl, 10% volume / volume glycerol). Fluorescence was measured after 24 h incubation at 29°C. The first four pairs were controls: sfGFP and deGFP were intact fluorescent proteins, while MBP-GFP 11 and GFP 1-10 The ten samples have the same amount of MBP-GFP. 11 , but with an increased molar excess of recombinant GFP 1-10 The data also showed that relative to GFP 11 Peptide tag increases molar excess of GFP 1-10 Detection of the polypeptide results in an enhanced fluorescent signal.
[0096] Fig. 9 sfGFP 11 Tagging with recombinant sfGFP 1-10 Complementation of the assays was inhibited in the presence of 0.1% weight / volume Tween20 surfactant. Complementation assays were performed in cell-free lysates (σ70 Linear Master Mix, Arbor Bioscience). Fluorescence was measured with a plate reader after 24 h of incubation. The first four pairs were controls: sfGFP and deGFP were intact fluorescent proteins, while MBP-GFP 11 and GFP 1-10 The three samples have the same amount of MBP-GFP. 11 , but with an increased molar excess of recombinant GFP 1-10 Detection of peptides.
[0097] Fig.10 : Images extracted from a time course experiment where droplets of cell-free protein synthesis (CFPS) lysate, optionally with a protein of interest (POI - here a variant of TdT or with GFP) were placed in a lysate containing 100 μM of lysate. 11 Peptide-tagged viral Mpro protease) DNA construct and / or with GFP 1-10 The DNA constructs of the peptides were incubated on the digital microfluidics device for 6 hours and imaged periodically. 11 DNA constructs and GFP labeled POI 1-10 The peptide droplets showed a significant increase in fluorescence during the experiment, as seen in the right-hand column of images. 1-10Lysates of DNA or POI alone showed no increase in fluorescence.
[0098] Fig.11 :show Fig.10 Figure 2 shows the real-time fluorescence increase seen in the droplets presented in Figure 2 (and the time point T = 1 hour, which is similar to T = 0 hours and is not included in the Figure 2). Fig.10 Quantification of fluorescence was performed in ImageJ and the values presented have been normalized by subtracting the background fluorescence seen in droplets containing CFPS lysate and GFP1-10 (i.e., no POI DNA construct, so no expression of the protein of interest, POI). 1-10 The droplets of both polypeptide and DNA constructs produced fluorescence above background.
[0099] Fig.12 : A graph showing real-time fluorescence of protein expression measured by a plate reader. Three different POIs (1: with sfGFP 11 Peptide-tagged TdT variants, 2: with different GFP 11 Peptide-tagged TdT variants, 3: with sfGFP 11 DNA constructs expressing peptide-tagged viral Mpro protease) were co-expressed with sfGFP in cell-free protein synthesis (CFPS) lysates. 1-10 Only the DNA constructs with GFP 11 Labeling of POI and GFP 1-10 Lysates of both DNA constructs showed an increase in fluorescence over time, whereas sfGFP alone 1-10 sfGFP 11 Lysates of POI-labeled DNA showed no increase in fluorescence over time.
[0100] Fig.13 : Separate ccGFP reagents were distributed and merged into a 384 droplet complementation array (white light image). Figure 1 384 droplets of MBP-ccGFP_S are shown 11 Allocation (from edge 1, 3 and 4 reservoirs). Figure 2 Display ccGFP 1-10 Dispense to form a second offset array of 384 droplets (768 droplets total; from edge 2 reservoir). Figure 3 Depiction of the final merged 384 droplet array (complementary incubations); A = 1 mg / mL FL ccGFP, B = TNG buffer, C = 1 mg / mL, D = 2.5 mg / mL ccGFP 1-10 .
[0101] Fig.14: Due to ccGFP 1-10 :MBP-ccGFP_S 11 Fluorescence image (blue light image) produced by complementation. Figure 1 The image in the figure was taken at t = 0 minutes. Figure 2 The image in Figure 1 was taken at t = 40 minutes, while Image 3 was taken at t = 110 minutes. Figure 3 A = 1 mg / mL FL ccGFP, B = TNG buffer, C = 1 mg / mL, D = 2.5 mg / mL ccGFP 1-10 All images were taken with an exposure time of 400ms.
[0102] Fig.15 :ccGFP 1-10 :MBP-ccGFP_S 11 eDrop complementation time course.
[0103] Fig.16 : Expression array distribution and incubation (white light image). Figure 1 An array of 192 droplets is shown after the Edge 1 component has been assigned. Figure 2 An array of 384 droplets is shown after the distribution of components at edges 1, 3, and 4. Figure 3 The 192 droplet arrays after expression array merging are shown. Figure 4 The 384 droplet arrays after splitting the expression array are shown.
[0104] Fig.17 : Expression array distribution and incubation (blue light image).
[0105] Fig.18 : Complementary array distribution and incubation. Figure 1 A complementary array of 768 droplets after edge 2 component distribution is shown (white light image). Figure 2 Shows an array of 384 droplets after complementary array merging and incubation (white light image). Figure 3 An array of 384 droplets after complementation incubation endpoint is shown (blue light image).
[0106] Fig.19 :eDrop complementary endpoint fluorescence. Panel A shows the recombinant MBP-ccGFP_S 11 ccGFP 1-10 Sub-figure B shows the expression of MBP-ccGFP_S 11 (LEC_576) and recombinant ccGFP 1-10 In situ complementation of the lysate.
[0107] Fig. 20 : Display ccGFP1-11 sequence and domain structure.
[0108] Fig.21 : Truncated ccGFP 11 Effect of the sequence of the binding domain on the fluorescence signal.
[0109] Fig. 22 : Truncated ccGFP 11 Effect of the sequence of the binding domain on the fluorescence signal.
[0110] Fig.23 : Experimental results of 24 different proteins expressed in droplets on an electrowetting on dielectric (EWoD) device in a reconstructed cell-free protein synthesis system. Each construct contains GFP 11 In the row labeled "Screening," GFP 1-10 The test substance is present from the beginning of expression. The row marked "end point" shows the absence of GFP 1-10 The detection substance was expressed for 10 hours, and then GFP was used 1-10 Fluorescence signal was detected for 5 hours of complementation of the substances. This experiment showed a significant difference between expression / complementation in the Screen BioInk compared to the "end point" assay.
[0111] Fig.24 : added to the MBP_GFP generated by CFPS 11 (sf or cc) ccGFP 1-10 Constructs and sfGFP 1-10 Normalized data for all constructs. 1-10 The constructs all had faster maturation times and high maximum fluorescence. DETAILED DESCRIPTION OF THE INVENTION
[0113] The present invention describes the use of a separate protein ccGFP for protein expression in an electrowetting device. Applicants have recognized that ccGFP provides several advantages over other separate fluorescent proteins, including brighter signals per molecule, faster complementation of the generated fluorescent signal, greater solubility and ease of preparation. ccGFP tolerates buffer conditions and denaturants such as urea to a large extent because the protein structure is highly stable. Other fluorescent proteins need to be refolded from inclusion bodies and are therefore sensitive to the presence of denaturants such as urea. Therefore, the separate ccGFP system is particularly advantageous for use in protein expression applications on electrowetting devices. When compared with other separate fluorescent proteins such as sfGFP, the ccGFP construct has a faster maturation time and a high maximum fluorescence of the normalized concentration, while the variability between different buffer compositions is lower due to the high folding stability.
[0114] Disclosed herein is a method for real-time monitoring of in vitro protein synthesis, comprising:
[0115] a. in vitro transcription and translation of a protein of interest fused to a peptide tag; and
[0116] b. Monitoring the presence of the peptide tag using another polypeptide that produces a detectable signal in the presence of the peptide tag.
[0117] Disclosed herein is a method for monitoring cell-free protein synthesis in droplets on a digital microfluidics device, comprising:
[0118] a. Cell-free transcription and translation of a protein of interest fused to a peptide tag; and
[0119] b. Monitoring the presence of the peptide tag using another polypeptide that produces a detectable signal in the presence of the peptide tag.
[0120] The peptide tag can be ccGFP 11 Tags. The sequence of tags can be selected from
[0121]
[0122] or a truncated form thereof.
[0123] The tag should contain at least the LQEHAVAK region. The tag length should be at least 13 amino acids.
[0124] The nucleic acid sequence used for the expression tag may be a truncated version of 5'GGTGAAACCATCCAGTTACAAGAACACGCCGTGGCCAAATATTTCACCGAA.
[0125] The tag sequence LQEHAVAK can be expressed using the sequence 5'TTACAAGAACACGCCGTGGCCAAA.
[0126] A method for cell-free expression of peptides or proteins in a digital microfluidics device is disclosed. Droplets with the components required for cell-free protein synthesis (CFPS), also known as in vitro protein synthesis, can be manipulated by electrokinesis to achieve and improve protein expression.
[0127] Electrowetting is the process of changing the wetting properties of a surface (which is generally hydrophobic) with an applied electric field. Microfluidic devices based on electrowetting manipulation of droplets or magnetic beads have been widely described. In the case of droplets in a channel, this can be achieved by allowing the droplets, for example in the presence of an immiscible carrier fluid, to travel through a microfluidic channel defined by a barrel wall or a microfluidic tube. Embedded in the barrel wall or tube wall are electrodes covered by a dielectric layer, each of which is connected to an A / C bias circuit that can be quickly opened and closed at intervals to change the electrowetting field characteristics of the layer. This produces the ability to guide droplets along a given path. As an alternative to microfluidic channel systems, digital microfluidics (DMF) can also be used to generate and manipulate droplets on a plane. Compared with channel-based microfluidics, DMF uses an alternating current on an electrode array to move fluid on the surface of the array. Therefore, liquids can be moved on an open device by electrowetting. Digital microfluidics achieves precise control of the movement of droplets, including droplet fusion and separation.
[0128] Cell-free protein synthesis, also known as in vitro protein synthesis or CFPS, is the use of biological machinery to produce peptides or proteins in a cell-free system, i.e., without the use of living cells. The in vitro protein synthesis environment is not limited to the cell wall, nor is it limited by the conditions necessary to maintain cell viability, and can rapidly produce any desired protein from a nucleic acid template, usually plasmid DNA or RNA from in vitro transcription. CFPS has been known for decades, and many commercial systems are available. Cell-free protein synthesis includes systems based on crude lysates (Cold Spring Harb Perspect Biol. 2016 Dec; 8 (12): a023853) and systems based on recombinant, purified molecular reagents, such as the PURE system for producing proteins (Methods Mol Biol. 2014; 1118: 275-284). CFPS requires high concentrations of biomacromolecules, including DNA, RNA, proteins, polysaccharides, molecular crowding agents, etc. (Febs Letters 2013, 2, 58, 261-268).
[0129] To date, digital microfluidics, electrowetting on dielectrics (EWoD) and electrokinesis in general have found only limited use in cell-free based biological applications, primarily due to biofouling, where biological components such as proteins, nucleic acids, crude cell extracts and other biological products adsorb and / or denature to hydrophobic surfaces. It is well known in the art that biofouling limits the ability of EWoD devices to manipulate droplets containing biomacromolecules. Wheeler et al. reported a maximum actuation time of 30 minutes for droplets on an EWoD device containing biological media before biofouling inhibited EWoD-based droplet actuation (Langmuir 2011, 27, 13, 8586-8594).
[0130] Digital microfluidics can be performed in air-filled systems, where droplets are manipulated on surfaces in the air. However, at elevated temperatures or over extended periods of time, volatile aqueous droplets dry onto the surface only by evaporation. This problem is complicated by the high surface area to volume ratio of nanoliter and microliter sized droplets. Therefore, air-filled systems are generally not suitable for protein expression, where the temperature of the system needs to be maintained at a temperature suitable for enzyme activity, and the duration of synthesis needs to be extended so that the synthesized protein level can be detected.
[0131] The expression of proteins generally requires an adequate supply of oxygen. The most convenient and high-yield way to power CFPS is via oxidative phosphorylation, where O2 is used as the final electron acceptor; however, there are other ways that involve supplementing with energy molecules that do not participate in oxidative phosphorylation. In the restricted microfluidic or digital microfluidic systems of droplets, there is not enough oxygen available to achieve efficient protein synthesis.
[0132] Described herein is an improved method for achieving cell-free expression of peptides or proteins in a digital microfluidic device. A method for cell-free expression of peptides or proteins in a microfluidic device is included, wherein the method includes one or more droplets containing a nucleic acid template (i.e., DNA or RNA) and a cell-free system having components for expressing proteins in an oil-filled environment, and using electrokinesis to move the droplets. The components for cell-free protein synthesis droplets can be pre-mixed before introduction into the digital microfluidic device, or mixed on the digital microfluidic device.
[0133] The droplets can be repeatedly moved for a period of at least 30 minutes while expressing the protein. The droplets can be repeatedly moved for a period of at least two hours while expressing the protein. The droplets can be repeatedly moved for a period of at least 12 hours while expressing the protein. The action of moving the droplets causes oxygen to be supplied to the droplets and dispersed throughout the droplets. The action of moving improves protein expression levels compared to droplets that remain stationary.
[0134] Any electrical motion means may be used to move the droplets. The droplets may be moved using electrowetting on dielectrics (EWoD). The electrical signals on an EWoD or optical EWoD device may be delivered through segmented electrodes, active matrix thin film transistors, or digital micromirrors.
[0135] The oil in the device can be any water-immiscible liquid. The oil can be a mineral oil, a silicone oil, an alkyl-based solvent such as decane or dodecane, or a fluorinated oil. Before or during the expression process, the oil can be oxygenated. Alternatively, the device can be an air-filled device in which droplets containing cell-free protein synthesis reagents are quickly moved to a position and fixed to an array under a humidified gas to prevent evaporation. Humidification can be achieved by closing or sealing a digital microfluidic device and providing a reagent reservoir on board. In addition, humidification can be achieved by connecting an aqueous reservoir to a closed or sealed digital microfluidic device. The aqueous reservoir can have a defined temperature or solute concentration to provide a specific relative humidity (e.g., a saturated potassium sulfate solution at 30°C).
[0136] The source of supplementary oxygen can be supplied to the droplets. For example, during protein expression, droplets or bubbles containing gaseous or dissolved oxygen can merge with the droplets. In addition, the source of supplementary oxygen can be obtained by oxygenating the oil used as a filler medium. It is well known in the art that oils, such as hexadecane, HFE-7500, etc. can be oxygenated to support cell growth, particularly the oxygen demand of E. coli cell growth (RSC Adv., 2017, 7, 40990-40995). Oxygenation can be achieved by aerating the oil with pure oxygen or atmospheric air.
[0137] Droplets can be formed prior to entering a microfluidic device and flow into the device. Alternatively, droplets can be merged on the device. A method is included that includes merging a first droplet containing a nucleic acid template, such as a plasmid, with a second droplet containing a cell-free extract having components for protein expression to form a combined droplet capable of cell-free protein synthesis.
[0138] The droplet can be split on the device before or after expression. Included herein is a method further comprising splitting the aqueous droplet into a plurality of droplets. If desired, the split droplets can be screened with other additives. Included is a method wherein one or more split droplets are combined with an additive droplet for screening.
[0139] Cell-free expression of peptide or protein can use cell lysate with reagents for realizing protein expression. Common components of cell-free reaction include energy source, amino acid supply source, auxiliary factor such as magnesium, and relevant enzyme. Cell extract is obtained by removing cell wall, DNA genome and other fragments by centrifugation through cracking the cell of interest. What remains is cell machinery, including ribosome, aminoacyl-tRNA synthetase, translation initiation factor and elongation factor, nuclease etc. Once suitable nucleic acid template is added, the expression machine of cell origin can be used to express nucleic acid template as peptide or protein.
[0140] Any specific nucleic acid template can be expressed using the system described herein. Three types of nucleic acid templates for CFPS include plasmids, linear expression templates (LETs), and mRNA. Plasmids are circular templates that can be produced in cells or produced by synthesis. LETs can be prepared via PCR. Although LETs are easier and faster to prepare, the yield of plasmids is generally higher in CFPS. mRNA can be produced by an in vitro transcription system. The method uses a single nucleic acid template per droplet. The method can use multiple droplets with different nucleic acid templates per droplet.
[0141] The energy source is an important part of the cell-free reaction. Typically, a separate mixture containing the required energy source, along with a supply of amino acids, is added to the extract for the reaction. Common sources are phosphoenolpyruvate, acetyl phosphate, and creatine phosphate. During expression, the energy source can be supplemented by adding other reagents to the droplets during the process.
[0142] The cell-free extract with components for protein expression contains everything required for protein expression except the nucleic acid template. Therefore, the term includes all related ribosomes, enzymes, initiators, nucleotide monomers, amino acid monomers, metal ions and energy sources. Once the nucleic acid template is added, the expression of the protein begins without the need for other reagents.
[0143] Therefore, before adding the template, the cell lysate can be supplemented with additional reagents. Cell-free extracts with components for protein expression will generally be made as bulk reagents or 'reaction mixtures (master mix)', which can be formulated into many identical droplets before different templates are added to different droplets respectively. Common cell extracts currently used are made from Escherichia coli (ECE), rabbit reticulocytes (RRL), wheat germ (WGE), insect cells (ICE) and Kluyveromyces yeast (D2P system). All of these extracts are commercially available.
[0144] Cell-free systems can be assembled from the required reagents, rather than from cell extracts. Systems based on reconstructed, purified molecular reagents are commercially available, such as the PURE system for making proteins, which can be used as provided. The PURE system consists of all enzymes involved in transcription and translation, as well as highly purified 70S ribosomes. The protein synthesis reactions of the PURE system lack proteases and ribonucleases, which are often present as undesirable molecules in cell extracts.
[0145] The term digital microfluidic device refers to a device with a two-dimensional array of planar microelectrodes. The term excludes any device that only has droplets in an oil stream in a channel. By activating specific electrodes, the droplets are moved on the surface by electrodynamic forces. After electrode activation, the dielectric layer becomes less hydrophobic, allowing the droplets to spread onto the surface. The arrangement of digital microfluidic (DMF) devices is known in the art and depends on the substrate used, the electrodes, the configuration of those electrodes, the use of dielectric materials, the thickness of the dielectric material, the hydrophobic layer, and the applied voltage.
[0146] Once the CFPS reagents have been enclosed in a droplet, additional reagents can be provided by merging the original droplet with a second droplet. The second droplet can carry any desired additional reagents, including, for example, an oxygen or 'power' source, or a test agent that is desired to be exposed to the expressed protein.
[0147] A method is disclosed wherein a first droplet on a device contains reagents for cell-free transcription and translation of a protein of interest fused to a ccGFP11 peptide tag; a second droplet on the device contains ccGFP 1-10 The droplets can be merged on the device, and once the first and second droplets are merged on the device, the presence of a detectable signal generated can be monitored. The signal is detected via ccGFP 11 The peptide tag indicates the amount of protein expressed. The merging can be before or after expression occurs, thus being a real-time or endpoint measurement. A method is disclosed wherein a second droplet is added to a first droplet after expression of the protein of interest. A method is disclosed wherein a second droplet is added to a first droplet before expression of the protein of interest.
[0148] The droplets may be aqueous droplets. The droplets may contain an oil-immiscible organic solvent, such as, for example, DMSO. The droplets may be a mixture of water and a solvent, provided that the droplets do not dissolve into the bulk oil.
[0149] The droplets can be in a bulk oil phase. During expression, the dry gas environment simply dries the bubbles to the surface, leaving behind comet-like streaks of dry material by evaporation. Thus, the device is used for liquid filling of the expression process. Alternatively, the aqueous droplets can be in a humidified gas environment. The air-filled device can be sealed and humidified to provide an environment that reduces evaporation of the CFPS droplets.
[0150] Thus, droplets containing a cell-free extract with components for protein expression will generally be in an oil-filled environment before the nucleic acid template is added to the droplets. The template can be added by merging droplets on the microfluidic device. Alternatively, the template can be added to droplets outside the device and then flowed into the device for the expression process. For example, the expression process can be initiated on the device by increasing the temperature. Expression systems generally operate best at temperatures above standard room temperature, such as at or above 29°C.
[0151] The expression process generally takes several hours. Therefore, the process should be maintained for at least 30 minutes or 1 hour, generally at least 2 hours. Expression can be maintained for at least 12 hours. During the expression process, the droplets should be moved within the device. Movement can improve the process by mixing the reagents and ensuring that there is enough oxygen available within the droplets. Movement can be continuous, or it can be repeated with intermediate time periods without movement.
[0152] Thus, while expressing a protein, the aqueous droplets may be repeatedly moved for a period of at least 30 minutes or 1 hour. While expressing a protein, the aqueous droplets may be repeatedly moved for a period of at least two hours. While expressing a protein, the aqueous droplets may be repeatedly moved for a period of at least 12 hours. The action of moving the droplets enables mixing within the droplets and enables the supply of oxygen or other agents to the droplets. The action of moving improves protein expression levels compared to droplets that remain stationary.
[0153] A method is disclosed, comprising transcribing a nucleic acid sequence comprising the sequence of SEQ ID 16 or 17:
[0154] SEQ ID NO: 16
[0155]
[0156] SEQ ID NO: 17
[0157]
[0158] This sequence can be repeated to express multiple ccGFP amino acid tags. Transcription can be performed in droplets on a digital microfluidics device. 11 Tag the expressed protein with ccGFP 1-10 When the proteins are complementary, a fluorescent signal is obtained.
[0159] Digital microfluidics (DMF) refers to a two-dimensional planar platform for a lab-on-a-chip system based on the manipulation of microdroplets. Droplets can be distributed, moved, stored, mixed, reacted or analyzed on a platform with a set of insulated electrodes. Digital microfluidics can be used with analytical analysis processes such as mass spectrometry, colorimetry, electrochemistry and electrochemiluminescence.
[0160] Droplets can be moved using any means of electrical motion. Aqueous droplets can be moved using electrowetting on dielectrics (EWoD). Electrowetting on dielectrics (EWoD) is a variation of the electrowetting phenomenon based on dielectric materials. In the EWoD process, a droplet of a conductive liquid is placed on a dielectric layer with insulating and hydrophobic properties. Upon activation of the electrodes, the dielectric layer becomes less hydrophobic, causing the droplet to spread over the surface.
[0161] The electrical signal on the EWoD or optically activated amorphous silicon (a-Si) EWoD device can be delivered through segmented electrodes, active matrix thin film transistors or digital micromirrors. Optically activated s-Si EWoD devices are well known in the art and are used to drive droplets (J. Adhes. Sci. Technol., 2012, 26, 1747-1771).
[0162] The oil in the device can be any water-immiscible or hydrophobic liquid. The oil can be mineral oil, silicone oil, alkyl-based solvents such as decane or dodecane, or fluorinated oil. The air in the device can be any humidified gas.
[0163] A source of supplemental oxygen may be provided to the droplets. For example, during protein expression, droplets or bubbles containing gaseous or dissolved oxygen may merge with aqueous droplets. Alternatively, the source of oxygen may be a molecular source that releases oxygen. Alternatively, the droplets may be moved to an air / liquid boundary to achieve increased diffusion of oxygen from the gaseous environment. Alternatively, the oil may also be oxygenated. Alternatively, the droplets may be present in a humidified air-filled device.
[0164] Droplets can be formed prior to entering a microfluidic device and flow into the device. Alternatively, droplets can be merged on the device. A method is included that includes merging a first droplet containing a nucleic acid template, such as a plasmid, with a second droplet containing a cell-free system having components for protein expression to form a droplet.
[0165] The droplet can be split on the device before, during or after expression. Included herein is a method further comprising splitting the droplet into a plurality of droplets. If desired, the split droplets can be screened with other additives. Included is a method wherein one or more split droplets are combined with an additive droplet for screening.
[0166] Through affinity tags, such as FLAG-tag, HIS-tag, GST-tag, MBP-tag, STREP-tag or other forms of affinity tags, CFPS expressed proteins can be immobilized on solid support affinity resins, and fresh batches of CFPS reagents can be delivered on the resin. Therefore, updated reagents can be used to perform protein synthesis, carefully mimicking the industrial methods of continuous flow (CF) and continuous exchange (CE) CFPS. By mimicking CF- and CE-CFPS, users can scale up their CFPS manufacturing methods.
[0167] Droplets can be driven on hydrophobic surfaces on digital microfluidic devices (ACSNano 2018, 12, 6, 6050-6058). The hydrophobic surface can be a hydrophobic surface such as polytetrafluoroethylene (PTFE), Teflon AF (DuPont Inc), CYTOP (AGCChemicals Inc) or FluoroPel (Cytonix LLC). The hydrophobic surface can be modified in such a way as to reduce biofouling, particularly biofouling caused by exposure to CFPS reagents or nucleic acid reagents. The hydrophobic surface can also be superhydrophobic, such as NeverWet (NeverWet LLC) or Ultra-Ever Dry (FlotechPerformance Systems Ltd). Compared with general fluorocarbon-based hydrophobic surfaces, superhydrophobic surfaces prevent biofouling. Therefore, superhydrophobic surfaces extend the ability of digital microfluidic devices to move CFPS droplets and general solutions containing biopolymers (RSC Adv., 2017, 7, 49633-49648). The hydrophobic surface can also be a slippery liquid-infused porous surface (SLIPS), which can be formed by infusing a porous PTFE membrane with Krtox-103 oil (DuPont) (Lab Chip, 2019, 19, 2275).
[0168] The droplets may also contain additives to reduce the effects of biofouling on the digital microfluidic surface. Specifically, the droplets containing the CFPS component may also contain additives, such as surfactants or detergents, to reduce the effects of biofouling on the hydrophobic or superhydrophobic surfaces of the digital microfluidic device (Langmuir 2011, 27, 13, 8586-8594). Such droplets may use antifouling additives such as TWEEN 20, Triton X-100 and / or Pluronic F127. Specifically, the droplets containing the CFPS component may contain 0.1% volume / volume TWEEN20, 0.1% volume / volume Triton X-100, and / or 0.08% weight / volume Pluronic F127.
[0169] For electrowetting on dielectrics (EWoD), the change in the contact angle of the reagent after applying an electric potential is an inverse function of the surface tension. Therefore, for low voltage EWoD runs, the reduction in surface tension is achieved by adding a surfactant to the reagent, which for CFPS reactions means adding to the lysate and adding to the DNA. This results in dilution of the lysate, and it has been seen in experiments that dilution or otherwise doping the lysate results in a decrease in the expression level of the protein of interest. Therefore, performing CFPS on the DMF in which the surfactant is added to the solution being moved will inevitably result in dilution and doping of the lysate, thereby reducing protein expression levels. In addition to being a problem in itself, this further complicates the prediction of protein yield in the tube by extrapolating the results on the DMF. Another disadvantage of having to add a surfactant to the sample is that this increases the time required for sample preparation and also increases the possibility of inconsistent results due to 'user error' because there are more reagents to handle. Another disadvantage of having to add a surfactant to the sample is that some downstream operations are hindered. For example, if the protein of interest is expressed in a cell-free system with a GFP11 (or similar) peptide tag, its downstream complementation with a GFP1-10 (or similar) detector polypeptide is hampered in the presence of surfactant. Figure 8 and Fig. 9 Therefore, it is advantageous to remove the surfactant from the aqueous phase.
[0170] Instead of adding a surfactant to the aqueous sample, a surfactant, such as a sorbitan ester, such as Span85 (e.g., Sorbitan trioleate, Sigma Aldrich, SKU8401240025), can be added to the oil. This has the advantage of allowing the CFPS reaction to be carried out in DMF without dilution or doping. In addition, it simplifies the sample preparation process for setting up the reaction, improving ease of use and consistency of results. Using 1% weight / weight Span85 in dodecane enables undiluted CFPS reactions in DMF and undiluted detection of expressed non-fluorescent proteins. Other surfactants besides Span85 and oils besides dodecane can be used. A range of concentrations of Span85 can be used. The surfactant can be nonionic, anionic, cationic, amphoteric, or a mixture thereof. The oil can be a mineral oil or a synthetic oil, including silicone oil, petroleum oil, and perfluorinated oil. Surfactants can have an adverse effect on (1) the CFPS reaction and (2) the efficiency of the detection system (if the detection system involves complementation of the label and the detectable substance). For example, by performing the CFPS reaction on DMF with an oil-surfactant mixture, detection of the expressed protein can also be performed without dilution and without the addition of aqueous surfactant. Surfactants have been shown to reduce the expression of some detection systems, including but not limited to separate ccGFP (e.g., ccGFP 11 / ccGFP 1-10 ) system, it would be beneficial to remove the surfactant from the reagent mixture and instead add it to the oil.
[0171] The peptide tag can be attached to the C-terminus or N-terminus of the protein. The peptide tag can be a component of green fluorescent protein (ccGFP). For example, the peptide tag can be ccGFP 11 , the other polypeptide can be ccGFP 1-10 The peptide tag may be a component of sfCherry. The peptide tag may be a component of sfCherry 11 , and the other polypeptide can be sf℃herry 1-10 .
[0172] A protein can be fused to multiple tags. For example, a protein can be fused to multiple ccGFP 11 Peptide tag fusion and multiple ccGFP 1-10 For example, a protein can be synthesized with multiple sfCherry 11 Peptide tag fusion and multiple sfCherry 1-10 The protein of interest can be synthesized in the presence of one or more sfCherry 11 Peptide tag and one or more ccGFP 11Peptide tag fusion and one or more ccGFP 1-10 Peptide and one or more sfCherry 1-10 Synthesis occurs in the presence of polypeptides.
[0173] After expression, the protein can be purified on the device. A method is disclosed, comprising
[0174] a. Take a digital microfluidic device having a planar electrode array;
[0175] b. synthesizing a protein of interest with a bound tag in a droplet on the device;
[0176] c. Capturing the protein via the binding tag, thereby immobilizing the protein;
[0177] d. Using electrodes to move the droplets, thereby removing the synthesized protein from the droplets;
[0178] e. optionally washing the immobilized protein; and
[0179] f. Optionally release the protein into other droplets.
[0180] The binding moiety tag can be a subcomponent of the fluorescent protein. Thus, the fully assembled protein becomes fluorescent. For example, if the fixed material contains ccGFP 1-10 , tagged with ccGFP 11 The peptides, complemented to form an immobilized fluorescent ccGFP, enable simultaneous monitoring and purification. The immobilized material can be washed and then eluted by disrupting the complementation to separate ccGFP, for example by using salt or temperature.
[0181] A method is disclosed, comprising:
[0182] a. Take a digital microfluidic device having a planar electrode array;
[0183] b. Synthesis of one or more ccGFPs in droplets on the device 11 Label the protein of interest;
[0184] c. Via ccGFP 11 The tag captures the protein, thereby immobilizing it;
[0185] d. Using electrodes to move the droplets, thereby removing the synthesized protein from the droplets;
[0186] e. optionally washing the immobilized protein; and
[0187] f. Optionally release the protein into other droplets.
[0188] Fixed ccGFP can be used 1-10Once fixed via complementation, the protein becomes fluorescent. Therefore, correctly expressed proteins can be identified by binding to the fixed ccGFP 1-10 Complex to monitor and purify.
[0189] Device
[0190] Manipulation of droplets by applying an electric potential can be achieved on electrodes covered with an insulator or dielectric or a series of insulators or dielectrics. Manipulation of droplets caused by an applied electric potential is called electrowetting. The electromotion occurs due to a non-uniform electric field that affects the hydrostatic equilibrium of a dielectric liquid (dielectrophoresis or DEP) or a change in the contact angle of the liquid on a solid surface (electrowetting on dielectrics or EWoD). DEP can also be used to generate forces on polarizable particles to induce their movement. The electrical signal can be transmitted to discrete electrodes, transistors, transistor arrays, or semiconductor membranes, whose electrical properties can be modulated by optical signals.
[0191] The EWoD phenomenon occurs when a droplet is driven between two parallel electrodes covered with a hydrophobic insulator or dielectric. The electric field at the electrode-electrolyte interface induces a change in surface tension, which causes the droplet to move due to a change in the droplet contact angle. The electrowetting effect can be quantitatively treated using the Young-Lippmann equation:
[0192] cosθ-cosθ0=(1 / 2γLG)cV 2
[0193] where θ0 is the contact angle when the electric field across the interfacial layer is zero, yLG is the liquid-gas tension, and c is the specific capacitance (as ε r .ε0 / t is given, where ε r is the dielectric constant of the insulator / dielectric, ε0 is the permittivity of a vacuum, t is the thickness), and V is the applied voltage or potential. Therefore, the change in contact angle (induced droplet movement) is a function of surface tension, potential, dielectric thickness, and dielectric constant.
[0194] When a droplet is driven by an EWoD, two sets of opposing forces act on it: the electrowetting force induced by the electric field and the drag force, which consists of the drag force caused by the interaction of the droplet with the filler dielectric and the contact line friction (reference). The minimum voltage (threshold voltage) applied to balance the electrowetting force with the sum of all the drag forces is determined by the thickness of the insulator / dielectric and the dielectric contact ratio (t / ε). r ) 1 / 2 Therefore, in order to reduce the driving voltage, it is necessary to reduce (t / ε r ) 1 / 2(i.e. increasing the dielectric constant or reducing the thickness of the insulator / dielectric). To achieve low voltage actuation, thin insulator / dielectric layers must be used. However, the deposition of high-quality thin insulator / dielectric layers is a technical challenge, and these thin layers are easily damaged before the desired electrowetting contact angle is large enough to drive the droplets. Therefore, most academic studies report the use of much higher voltages of >100V on easily manufactured thick dielectric films (>3 microns) to achieve electrowetting.
[0195] However, high voltage EWoD-based devices with thick dielectric films have limited industrial applicability, primarily due to their limited droplet multiplexing capabilities. The use of low voltage devices including thin film transistors (TFTs) and optically activated amorphous silicon layers (a-Si) has paved the way for industrial applications of EWoD-based devices due to their greater flexibility in addressing electrical signals in a highly multiplexed manner. The driving voltage of TFTs or optically activated a-Si is low (typically <15V). A bottleneck in the manufacture and therefore adoption of low voltage devices has been the technical challenge of depositing high quality thin film insulators / dielectrics. Therefore, there has been a particular need to improve the manufacture and composition of thin film insulator / dielectric devices.
[0196] Typically, electrodes (or array elements) for EWoDs are covered with either (i) a hydrophilic insulator / dielectric and a hydrophobic coating or (ii) a hydrophobic insulator / dielectric. Commonly used hydrophobic coatings include fluoropolymers such as Teflon AF 1600 or CYTOP. The thickness of such materials as hydrophobic coatings on dielectrics is generally <100 nm and may have defects in the form of pinholes or porous structures; therefore, it is particularly important that the insulator / dielectric is pinhole-free to avoid electrical shorts. Teflon has also been used as an insulator / dielectric, but has higher voltage requirements due to its low dielectric constant and the thickness required to make it pinhole-free. Other hydrophobic insulator / dielectric materials may include polymer-based dielectrics such as those based on siloxane, epoxy resins (such as SU-8), or polyparaxylene (e.g., polyparaxylene N, polyparaxylene C, polyparaxylene D, or polyparaxylene HT). Teflon is still used as a hydrophobic outer coating for these insulator / dielectric polymers due to minimal contact angle hysteresis and large contact angles with aqueous solutions. However, there are difficulties in reliably manufacturing pinhole-free coatings of parylene or SU-8 <1 micron; therefore, the thickness of these materials is generally kept at 2-5 microns, at the expense of increased electrowetting voltage requirements. It has also been reported that conventional EWoD devices with parylene C are prone to breakage and instability for repeated droplet manipulations using cell culture media. Multilayer insulator devices deposited with metal oxides and parylene C films have been used to make more robust insulators / dielectrics and can operate at lower applied voltages. Inorganic materials, such as metal oxides and semiconductor oxides, which are commonly used as "gate dielectrics" in the CMOS industry, have been used as insulators / dielectrics for EWoD devices. They offer the advantage of thin film deposition (<100 nm) using standard clean room methods. These materials are inherently hydrophilic, require additional hydrophobic coatings, and are prone to pinhole formation due to the thin film layer deposition process. Together with the need for lower voltage operation of EWoD, recent development efforts have focused on (1) using materials with improved dielectric properties (e.g., using insulators / dielectrics with high dielectric constants), and (2) optimizing manufacturing methods to make the insulators / dielectrics pinhole-free to avoid dielectric breakdown.
[0197] The operation of EWoD devices is affected by contact angle saturation and hysteresis, which is believed to be caused by one or a combination of the following phenomena: (1) charge entrapment in the hydrophobic membrane or insulator / dielectric interface, (2) adsorption of ions, (3) thermodynamic contact angle instability, (4) dielectric breakdown of the dielectric layer, (5) electrode-electrode-insulator interface capacitance (caused by double layer effects), and (6) fouling of the surface (such as fouling of the surface by biomacromolecules). One of the adverse effects of such hysteresis is the reduction of the operational lifetime of EWoD-based devices.
[0198] Contact angle hysteresis is believed to be the result of charge accumulation at the interface or within the hydrophobic insulator after a few runs. Due to this charging phenomenon, the required driving voltage increases, leading to an eventual catastrophic dielectric breakdown. The most likely explanation is that pinholes at the insulator / dielectric may allow the liquid to come into contact with the electrode, leading to electrolysis. Hydrophobic insulators that are prone to pinholes or porosity further promote electrolysis.
[0199] Most studies used to understand contact angle hysteresis on EWoD are based on short time scales and conducted with low conductivity solutions. Long duration actuation (e.g., >1 hour) and high conductivity solutions (e.g., 1 M NaCl) may produce several effects other than electrolysis. Ions in solution can permeate through the hydrophobic coating (under an applied electric field) and interact with the underlying insulator / dielectric. Ion penetration can lead to (1) changes in the dielectric constant due to charge trapping (which is different from interfacial charging) and (2) changes in the surface potential of the pH-sensitive metal oxide. Both can lead to a reduction in the electrowetting force that manipulates aqueous droplets, resulting in contact angle hysteresis. The inventors have previously discovered that damage from high conductivity solutions reduces electrowetting on the electrode by inhibiting modulation of the contact angle when an electric field is applied, or makes electrowetting impossible on the electrode.
[0200] An electrokinetic device includes a first substrate having an electrode matrix, wherein each matrix electrode is coupled to a thin film transistor, and wherein the matrix electrodes are coated with a functional coating, the functional coating comprising: a dielectric layer in contact with the matrix electrodes, a conformal layer in contact with the dielectric layer, and a hydrophobic layer in contact with the conformal layer; a second substrate including a top electrode; a spacer disposed between the first substrate and the second substrate and defining an electrokinetic working space; and a voltage source operably coupled to the matrix electrodes.
[0201] The dielectric layer may include silicon dioxide, silicon oxynitride, silicon nitride, hafnium oxide, yttrium oxide, lanthanum oxide, titanium dioxide, aluminum oxide, tantalum oxide, hafnium silicate, zirconium oxide, zirconium silicate, barium titanate, lead zirconate titanate, strontium titanate or barium strontium titanate. The thickness of the dielectric layer may be 10nm to 100μm. A combination of more than one material may be used, and the dielectric layer may include more than one sublayer, which may be made of different materials.
[0202] The conformal layer may comprise parylene, siloxane or epoxy. It may be a thin protective parylene coating between an insulating dielectric and a hydrophobic coating. Typically, parylene is used as a dielectric layer on simple devices. In the present invention, the reason for depositing parylene is not to improve insulating / dielectric properties, such as reducing pinholes, but as a conformal layer between a dielectric layer and a hydrophobic layer. The inventors have found that, in contrast to other similar insulating coatings of the same thickness, such as PDMS (polydimethylsiloxane), parylene prevents contact angle hysteresis caused by high conductivity solutions or solutions that deviate from neutral pH for a long time. The thickness of the conformal layer may be from 10 nm to 100 μm.
[0203] The hydrophobic layer may comprise a fluoropolymer coating, a fluorinated silane coating, a manganese oxide polystyrene nanocomposite, a zinc oxide polystyrene nanocomposite, precipitated calcium carbonate, a carbon nanotube structure, a silica nanocoating, or a slippery liquid-infused porous coating.
[0204] The element may include one or more of a plurality of array elements, each element containing element circuitry; discrete electrodes; a thin film semiconductor whose electrical properties can be modulated by incident light; and a thin film photoconductor whose properties can be modulated by incident light.
[0205] The functional coating may comprise a dielectric layer comprising silicon nitride, a conformal layer comprising parylene and a hydrophobic layer comprising an amorphous fluoropolymer. This has been found to be a particularly advantageous combination.
[0206] The electro-motion device may include a controller for regulating the voltage supplied to the individual matrix electrodes. The electro-motion device may include a plurality of scan lines and a plurality of gate lines, wherein each thin film transistor is coupled to a scan line and a gate line, and the plurality of gate lines are operably connected to the controller. This enables all individual elements to be individually controlled.
[0207] The second substrate may further include a second hydrophobic layer disposed on the second electrode. The first substrate and the second substrate may be disposed such that the hydrophobic layer and the second hydrophobic layer face each other, thereby defining an electromotion working space between the hydrophobic layers.
[0208] The method is particularly suitable for use with aqueous droplets having a volume of 1 μl or less.
[0209] The EWoD-based devices shown and described below are active matrix thin film transistor devices containing a thin film dielectric coating with a Teflon hydrophobic surface coating. These devices are based on devices described in E Ink's patent application entitled "Digital microfluidic device including dual substrates with thin film transistors and capacitive sensing", which is filed as U.S. Patent Application No. 2019 / 0111433 and is incorporated herein by reference.
[0210] An electrokinetic device is described herein, comprising:
[0211] A first substrate having an electrode matrix, wherein each matrix electrode is coupled to a thin film transistor, and wherein the matrix electrodes are coated with a functional coating comprising:
[0212] A dielectric layer in contact with the matrix electrodes,
[0213] a conformal layer in contact with the dielectric layer, and
[0214] a hydrophobic layer in contact with the conformal layer;
[0215] a second substrate including a top electrode;
[0216] A spacer disposed between the first substrate and the second substrate and defining an electrokinetic working space; and
[0217] A voltage source is operably coupled to the matrix electrodes.
[0218] An electrokinetic device is described herein, comprising:
[0219] A first substrate having an electrode matrix, wherein each matrix electrode is coupled to a thin film transistor, and wherein the matrix electrodes are coated with a functional coating comprising:
[0220] one or more dielectric layers comprising silicon nitride, hafnium oxide, or aluminum oxide in contact with the matrix electrode, a conformal layer comprising parylene in contact with the dielectric layer, and
[0221] a hydrophobic layer in contact with the conformal layer;
[0222] a second substrate including a top electrode;
[0223] A spacer disposed between the first substrate and the second substrate and defining an electrokinetic working space; and
[0224] A voltage source is operably coupled to the matrix electrodes.
[0225] The electrokinetic device may be used with other components such as, for example, means for heating and cooling the device or kits for introducing reagents as needed. Example
[0226] Example 1.
[0227] Created the sfGFP 11 -terminal deoxynucleotidyl transferase (sfGFP 11 _TdT) fusion protein cDNA sequence.
[0228] GFP 11-Terminal deoxynucleotidyl transferase (GFP11_TdT) fusion protein (SEQ ID NO: 1):
[0229]
[0230] sfGFP 11 -terminal deoxynucleotidyl transferase (GFP11_TdT) fusion protein includes 376aa of engineered TdT, which is connected to the 15aa N-terminal GFP via a 9aa linker. 11 Peptide tag attachment.
[0231] GFP 11 The _TdT cDNA sequence was cloned into the p70a vector and added (2 μl, 30 nM) to MyTXTLSigma70CFPS Master Mix (10 μl; Arbor Biosciences) to give a total reaction volume of 12 μl.
[0232] Then GFP 1-10 The solution (0.9 mg / ml; 364 mM urea) was added to the CFPS reaction at 0, 1, 2, 3, 4, 6 and 12 μl, respectively, to give final CFPS urea concentrations of 0, 28, 51, 72, 90, 120 and 180 mM.
[0233] The reactions were then incubated in 200 μl PCR tubes at 29° C. Pictures were taken under a 470 nm blue light illuminator using a 580 nm filter.
[0234] Figure 2 Display of sfGFP in CFPS reaction under blue light irradiation 11 _Real-time fluorescence detection of TdT. Figure 2 Optimization of sfGFP 1-10 The amount of solution, which is increasing the sfGFP 1-10 Trade-off between protein concentration and CFPS inactivation by increasing urea concentration.
[0235] Figure 3 sfGFP in CFPS response 11 _TdT was quantified by background-subtracted, real-time fluorescence detection. Fluorescence measurements were performed at the indicated time points using an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 1-10 Solution without GFP 11 Negative control CFPS reactions with _TdT p70a plasmid were used to subtract background fluorescence.
[0236] Figure 4 Shown is the measurement of expression in droplets on a microfluidic device.
[0237] Figure 4 In A, we can see that the tagged proteins (maltose binding protein, MBP, and sfGFP) were expressed in CFPS on eDrop. 11 Fusion, i.e., MBP-GFP 11 The first two columns contain CFPS lysates with expressed proteins, while the third column contains CPFS lysate controls (no expressed protein). Figure 4 The image of A was taken under darkfield illumination.
[0238] Figure 4 B shows that GFP was added to some droplets with expressed proteins. 1-10 Droplets of 10 μM, T = 6 hours. The larger droplets have concentrated recombinant sfGFP added to the CFPS lysate. 1-10 This image was taken under fluorescent light. Only droplets to which both the expressed marker protein and the complementary peptide were added showed fluorescence.
[0239] Figure 5-7 Real-time detection of protein expression. 1-10 The detection peptide is present from the beginning of the experiment. The fluorescent signal increases with the sfGFP 11 The label is expressed as an increase. These experiments were performed in a base fluid containing 0.2% Span 85 in dodecamethylpentasiloxane instead of an aqueous solution of Tween 20 and no surfactant in dodecane.
[0240] Figure 8 and 9 Shows the adverse effects of waterborne surfactants.
[0241] Figure 10-12 The detection of 1-10 ) and sfGFP 11 Co-expression of tagged proteins for real-time protein expression detection in tubes and droplets.
[0242] Example 2: Recombinant ccGFP 1-10 MBP_ccGFP_S 11 Protein complementation
[0243] The ACA eDrop device was preloaded with surfactant base fluid, which was then loaded onto the TTR prototype instrument and equilibrated at 29°C. 11 1mg / mL; ccGFP 1-1o1 mg / mL and 2.5 mg / mL; FL ccGFP 1 mg / mL, all in TNG buffer) were loaded onto the eDrop device by pipetting, combined with script-driven actuation of the TFT-pixels under the reagent port to form an aqueous reagent reservoir in the surfactant-based fluid in the device (e.g. Fig.13 shown).
[0244] Fig.13 Shown is the dispensing and merging of separate ccGFP reagents into a 384 droplet complementation array (white light image). Figure 1 384 droplets of MBP-ccGFP_S are shown 11 Allocation (from edge 1, 3 and 4 reservoirs). Figure 2 Display ccGFP 1-10 Dispense to form a second offset array of 384 droplets (768 droplets total; from edge 2 reservoir). Figure 3 Depiction of the final merged 384 droplet array (complementary incubations); A = 1 mg / mL FL ccGFP, B = TNG buffer, C = 1 mg / mL, D = 2.5 mg / mL ccGFP 1-10 .
[0245] A script is loaded that performs the following droplet operations:
[0246] 1) From ccGFP_S 11 Allocate 25px in the memory 2 droplets to form a 32×24 (n=384) droplet array ( Fig.13 ,son Figure 1 )
[0247] 2) From ccGFP 1-10 Allocate 25px in the memory 2 droplets to form a second 32×24 (n=768) droplet array, offsetting ccGFP_S 11 Droplet array ( Fig.13 ,son Figure 2 ).
[0248] 3) ccGFP_S 11 Droplet arrays with ccGFP 1-10 The droplet array merges to form 32×24 (n=384) 50px 2 Mixed droplet array ( Fig.13 ,son Figure 3 ).
[0249] 4) The mixed droplet array was incubated at 29°C for 4 hours with periodic droplet mixing to allow complementation of the separate ccGFP detection systems ( Fig.14 ).
[0250] Fig.14 Due to ccGFP 1-10 :MBP-ccGFP_S 11 Fluorescence image (blue light image) produced by complementation. Figure 1 The image in the figure was taken at t = 0 minutes. Figure 2 The image in Figure 1 was taken at t = 40 minutes, while Image 3 was taken at t = 110 minutes. Figure 3 Top, A = 1 mg / mL FL ccGFP, B = TNG buffer, C = 1 mg / mL, D = 2.5 mg / mL cc GFP 1-10 All images were taken with an exposure time of 400ms.
[0251] Endpoint fluorescence was extracted from the droplets and used to map [ccGFP 1-10 ] dependent complementary time course, such as Fig.15 Under the conditions tested, separate ccGFP complementation was confirmed on the eDrop and was completed within 4 hours.
[0252] Fig.15 Display ccGFP 1-10 :MBP-ccGFP_S 11 eDrop complementation time course.
[0253] Example 3: Recombinant and expressed ccGFP_S 11 POI and recombinant ccGFP 1-10 In situ complementation of protein lysates on eDrop (e.g. N22R183)
[0254] This example experimentally demonstrates that in the presence of in vitro transcription / translation reagents (E. coli lysate, PURExpress), MBP-ccGFP_S 11 Complementation of recombinant and in vitro expressed ccGFP 1-10 The ability to simulate separate GFP detection within a full eDrop workflow.
[0255] The ACA eDrop device was preloaded with surfactant base fluid and then loaded onto the TTR prototype instrument and equilibrated at 29° C. The edge reservoirs were loaded as described in Example 2 and arranged as shown in Table 1.
[0256]
[0257] A script is loaded that performs the following droplet operations:
[0258] 1) Allocate 25px from the edge 1 reservoir2 droplets to form a 12×16 (n=192) droplet array ( Fig.16 ,son Figure 1 ).
[0259] 2) Allocate 16px from edge 3 and 4 reservoirs 2 Droplets are formed to form a second 12×16 (n=192) droplet array, offset from the first droplet array. Total number of droplets in the array = 384 ( Fig.16 ,son Figure 2 )
[0260] 3) Merge two 192 droplet arrays to form a new 12×16 (n=192) 64px 2 Hybrid droplet expression array. Hybrid ( Fig.16 ,son Figure 3 ).
[0261] 4) Divide the array into 24×16 (n=384) 36px 2 Hybrid droplet expression array ( Fig.16 ,son Figure 4 ).
[0262] 5) The 384 droplet arrays were incubated at 29°C for 5 hours with periodic droplet mixing to allow expression to proceed (LEC_575, Fig.17 ).
[0263] 6) Allocate 36px from edge2 memory 2 Droplets are shifted to form a new 24×16 (n=384) droplet array. Total number of droplets in the array = 768 ( Fig.18 ,son Figure 1 ).
[0264] 7) Merge two 384 droplet arrays to form a new 24×16 (n=384) 81px 2 Hybrid droplet complementary array ( Fig.18 ,son Figure 2 ).
[0265] 8) The device was incubated for 5 hours with regular mixing to allow for separate ccGFP complementation to proceed ( Fig.18 ,son Figure 3 ).
[0266] Fig.16 Expression array distribution and incubation are shown (white light image). Figure 1 An array of 192 droplets is shown after the Edge 1 component has been assigned. Figure 2 An array of 384 droplets is shown after the distribution of components at edges 1, 3, and 4. Figure 3The 192 droplet arrays after the expression arrays were merged are shown. Figure 4 The 384 droplet arrays after splitting the expression array are shown.
[0267] Fig.17 Expression array distribution and incubation are shown (blue light images).
[0268] Fig.18 Complementation array assignment and incubation are shown. Figure 1 A complementary array of 768 droplets after edge 2 component distribution is shown (white light image). Figure 2 Shows an array of 384 droplets after complementary array merging and incubation (white light image). Figure 3 An array of 384 droplets after complementation incubation endpoint is shown (blue light image).
[0269] Under the conditions tested, separate ccGFP complementation was demonstrated on eDrop in the presence of the in vitro transcription / translation reagents Lys_01 (E. coli cell-free lysate) and Lys_24 (PURExpress), and for recombinant MBP-ccGFP_S 11 and expression of MBP-ccGFP_S 11 , separate ccGFP complementation was completed within 4 hours ( Fig.19 ).
[0270] Fig.19 Complementary endpoint fluorescence on eDrop is shown. Panel A shows recombinant MBP-ccGFP_S 11 ccGFP 1-10 Sub-figure B shows the expression of MBP-ccGFP_S 11 (LEC_576) and recombinant ccGFP 1-10 In situ complementation of the lysate.
[0271] Example 3 shows truncation of the ccGFP11 tag.
[0272] Full-length and 18 shortened MBP-ccGFP 11 Purified DNA of (v1) variants was compared with negative (-DNA) control and positive (ccGFP 11 (v1) purified protein) controls were used together with the reconstituted in vitro transcription / translation reactions. Aliquots of the samples were analyzed and then expressed in ccGFP 1-10 Before complementation, MBP-ccGFP was quantified by PAGE. 11 Relative expression of (v1). Fig.21 and 22 Display shortened ccGFP 11Effect of the GETIQLQEHAVAKYFTE tag. The GETIQ region can be removed, leaving LQEHAVAKYFTE. The YFTE region can be removed, leaving GETIQLQEHAVAK. Up to three amino acids can be removed from each end, leaving IQLQEHAVAKY.
[0273] Fig.23 Results of experiments showing 24 different proteins expressed in droplets on an electrowetting on dielectric (EWoD) device in a reconstituted cell-free protein synthesis system. Each construct contained GFP 11 In the row labeled "Screening," GFP 1-10 The test substance is present from the beginning of expression. The row marked "end point" shows the absence of GFP 1-10 The detection substance was expressed for 10 hours, and then GFP was used 1-10 Fluorescence signal of the test material complemented for 5 hours. This experiment showed a significant difference between expression / complementation in the "Screening Bio-Ink" compared to the "Endpoint" detection. The detection of protein clusters formed after expression using only the endpoint detection means that the protein aggregates after expression, thereby reducing the soluble yield. It can be clearly seen from the image that some constructs have spots, indicating that protein aggregates are likely present. The level of aggregation can identify conditions that are worth further testing and identify conditions with high levels of aggregation of proteins from which further purification is unlikely to obtain material.
[0274] Example 4 Comparison of ccGFP and sfGFP
[0275] Expression of ccGFP 1-10 sfGFP 1-10 sequences and exposed to the corresponding GFP at the same normalized concentration (0.93 mg / ml). 11 Binding partner.
[0276] ccGFP to be tested 1-10 Construct:
[0277] name: cc1 cc2 (concentrated) cc3 (dialysis) cc4 (dialysis / concentration) sf1(1x) sf2(2x) Dialysis: x x √ √ x x concentrate: x √ x √ x x mg / ml: 0.94 1.96 1.1 2.44 0.93 1.32
[0278] Dilute to make the stock solution 0.93 mg / ml:
[0279] <![CDATA[GFP 1-10 :]]> cc1 cc2(:concentrated) cc3 (dialysis) cc4 (dialysis / concentration) sf1(1x) sf2(2x) Stock solution mg / ml: 0.94 1.96 1.1 2.44 0.93 1.32 <![CDATA[Volume GFP 1-10 :]]> 99μl 47.4μl 84.5μl 38.1μl 100μl 70.5μl Volume TNG: 1μl 52.6μl 15.5μl 61.9μl 0μl 29.5μl
[0280] Perform CFPS reactions in 1.5 mL eppendorf tubes and incubate at 29 °C for 20 h with 5 nM final LEC DNA:
[0281]
[0282]
[0283]
[0284] For CFPS reactions 1-14, take 6 μl and add 54 μl GFP 1-1o or TNG buffer as detailed in the table above - incubate at 29°C in a plate reader and read sample fluorescence every 30 minutes for 12 hours. Seal the plate to reduce evaporation. Intensity reaches a plateau after 6 hours. Fig.24 As shown, purified ccGFP 1-10 Shows stronger overall fluorescence signal with faster onset time and maturation rate.
Claims
1. A method for monitoring cell-free protein synthesis in droplets on a digital microfluidics device, comprising: a. Cell-free transcription and translation with ccGFP 11 a peptide tag fused to a protein of interest; and b. Use of additional ccGFP 1-10 Peptide monitoring for the presence of a peptide tag, the addition of ccGFP 1-10 Peptide in the ccGFP 11 The presence of the peptide tag generates a detectable signal.
2. The method of claim 1, wherein the transcription and translation occur in a lysate system selected from a human lysate system, a rabbit reticulocyte lysate (RRL) system, a Chinese hamster ovary lysate system, a wheat germ cell-free system, an Escherichia coli whole cell lysate system, or a mixture thereof.
3. The method of any one of claims 1, wherein the in vitro transcription and translation occurs in a purified recombinant element (PURE) system.
4. The method of any one of claims 1 to 3, wherein the in vitro transcription and translation are coupled.
5. The method of any one of claims 1 to 4, wherein the ccGFP 11 The peptide tag is at least 13 amino acids in length and contains at least the sequence LQEHAVAK.
6. The method according to any one of claims 1 to 5, wherein the ccGFP 11 The peptide tag sequence is selected from or truncated thereof.
7. The method according to any one of claims 1 to 6, wherein the ccGFP 1-10 The polypeptide sequence has greater than 90% homology to SEQ ID NO: 4, 5 or 7.
8. The method of claim 7, wherein the sequence has greater than 95% homology to the following complete sequence:
9. The method of any one of claims 1 to 8, wherein the protein of interest is fused to a plurality of peptide tags.
10. The method of any one of claims 1 to 9, wherein the protein of interest is a single protein, such as TdT, IFNβ1-α, VEGF, or is a protein part of a protein-protein complex or a larger assembly, such as a bacteriophage.
11. The method of claim 10, wherein the protein of interest is terminal deoxynucleotidyl transferase (TdT) or a truncated form thereof, or a homologous amino acid sequence of terminal deoxynucleotidyl transferase (TdT) in other species, or a homologous amino acid sequence of Polμ, Polβ, Polλ and Polθ in any species, or a homologous amino acid sequence of X family polymerase in any species.
12. The method of any one of claims 1-11, wherein the droplets are in an oil phase.
13. The method of claim 12, wherein the droplets are in an oil phase and the oil phase comprises a surfactant.
14. The method of claim 13, wherein the surfactant in the oil phase is a nonionic surfactant.
15. The method of claim 14, wherein the surfactant is a sorbitan ester.
16. The method of claim 15, wherein the surfactant is Span 85.
17. The method of any of the preceding claims, wherein the first droplet on the device comprises 11 Cell-free transcription and translation of a protein of interest fused to a peptide tag; and a second droplet on the device contains ccGFP 1-10 The polypeptide is added to the droplet and once the first and second droplets are merged on the device, the presence of a detectable signal is monitored.
18. The method of claim 17, wherein the second droplet is added to the first droplet after expression of the protein of interest.
19. The method of claim 17, wherein the second droplet is added to the first droplet prior to expressing the protein of interest.
20. A method as claimed in any one of the preceding claims, comprising transcribing a nucleic acid sequence comprising one of SEQ ID 16 or 17 or a repeat of a sequence of SEQ ID 16 or 17: SEQ ID NO: 16 SEQ ID NO: 17 or a truncated form thereof.
21. A method according to any one of the preceding claims, comprising a. Take a digital microfluidic device having a planar electrode array; b. Synthesis of one or more ccGFPs in droplets on the device 11 Label the protein of interest; c. 1-10 The peptide droplets merge with the synthetic protein droplets; and d. Once the first and second droplets merge on the device, monitoring for the presence of a detectable signal.
22. A method according to any one of the preceding claims, comprising a. Take a digital microfluidic device having a planar electrode array; b. Synthesis of one or more ccGFPs in droplets on the device 11 Label the protein of interest; c. Via ccGFP 11 The tag captures the protein, thereby immobilizing it; d. Using electrodes to move the droplets, thereby removing the synthesized protein from the droplets; e. optionally washing the immobilized protein; and f. Optionally release the protein into other droplets.
23. The method of claim 22, wherein the immobilization is via immobilized ccGFP 1-10 was performed, and the fluorescence signal of the immobilized protein was monitored.
Citation Information
Patent Citations
Digital microfluidic devices including dual substrates with thin-film transistors and capacitive sensing
US20190111433A1
Protein- protein interaction detection system using fluorescent protein microdomains
US7666606B2
